It reflects that in lung cancer cell lines, the activation of MAPK1 (e.g., via arachidonic acid treatment) reduces lipid droplet formation through inhibiting the expression of FASN and proliferator-activated receptor gamma (PPARγ) [15]. The gene discussed is FASN; the disease is lung carcinoma.